STOCK TITAN
  1. Home
  2. Sec-filings
  3. DTIL
  4. [8-K] PRECISION BIOSCIENCES INC Reports Material Event

Precision BioSciences (NASDAQ: DTIL) shares HBV data, DMD trial timeline

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Precision BioSciences, Inc. furnished an updated corporate deck highlighting clinical progress in its gene-editing programs. In chronic hepatitis B, PBGENE-HBV from the ELIMINATE-B study showed liver biopsy data where it directly eliminated cccDNA, leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts. The company is targeting year-end 2026 for the next update on this program.

The deck also notes activation of a second clinical site at Washington University School of Medicine in St. Louis for the FUNCTION-DMD trial evaluating PBGENE-DMD for Duchenne muscular dystrophy, with initial safety data also targeted for year-end 2026. The information is furnished under Regulation FD and not deemed filed for liability purposes.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
HBV transcript reduction 1-log (10-fold) reduction cccDNA-derived transcripts in ELIMINATE-B study liver biopsies
Next HBV program update Year-end 2026 Targeted timing for PBGENE-HBV update
Initial DMD safety data Year-end 2026 Targeted timing for FUNCTION-DMD safety data
Clinical sites for FUNCTION-DMD Second clinical site Activation at Washington University School of Medicine
cccDNA medical
"PBGENE-HBV directly eliminated cccDNA through its primary mechanism"
cccDNA is a stable, circular form of viral genetic material that can hide inside infected cells and act like a permanent backup copy the virus uses to keep making new virus particles. For investors, cccDNA matters because treatments that reduce or eliminate this hidden template are more likely to produce long-lasting cures, shape clinical trial success and regulatory decisions, and therefore affect a drug’s commercial value and a company’s prospects.
PBGENE-HBV medical
"PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B"
ELIMINATE-B medical
"PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B"
FUNCTION-DMD medical
"FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy"
Duchenne muscular dystrophy medical
"FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy"
A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.
forward-looking statements regulatory
"contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001357874FALSE00013578742026-07-012026-07-01

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 8-K
________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 1, 2026
________________________________________________________
Precision BioSciences, Inc.
(Exact name of Registrant as Specified in Its Charter)
________________________________________________________
Delaware001-3884120-4206017
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
302 East Pettigrew St.
Suite A-100
Durham, North Carolina
27701
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 919 314-5512
(Former Name or Former Address, if Changed Since Last Report)
________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.000005 per shareDTIL
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 7.01 Regulation FD Disclosure.

Precision BioSciences, Inc. (the “Company”) has updated its corporate deck, which is available in the “Investors” portion of the Company’s website at https://investor.precisionbiosciences.com.

Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, this Item 7.01 of this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any registration statement or other filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.


Item 8.01 Other Events

In its updated corporate deck and as previously reported, the Company announced PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B, including liver biopsy data demonstrated that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts. The Company is targeting year-end 2026 for the next program update.

Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy with initial safety data targeted for year-end 2026.

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding expected program or data update, and commencement of the FUNCTION-DMD clinical trial. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including, without limitation, the risks referred to under the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2026, as such factors may be updated from time to time in the Company’s other filings with the Securities and Exchange Commission (“SEC”), which filings are accessible on the SEC’s website at www.sec.gov and the Investors & Media page of the Company’s website. All forward-looking statements speak only as of the date of this Current Report on Form 8-K, and except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.


Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
Exhibit
No.		Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PRECISION BIOSCIENCES, INC.
Date:July 1, 2026By:/s/ John Alexander Kelly
John Alexander Kelly
Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Precision BioSciences (DTIL) disclose about its hepatitis B program?

Precision BioSciences reported PBGENE-HBV liver biopsy data showing a 1-log (10-fold) reduction in cccDNA-derived transcripts. This indicates direct elimination of cccDNA in the ELIMINATE-B study, with the next program update targeted for year-end 2026.

What is PBGENE-HBV and what are the ELIMINATE-B study highlights?

PBGENE-HBV is Precision BioSciences’ candidate for chronic hepatitis B. In the ELIMINATE-B study, liver biopsy data showed PBGENE-HBV directly eliminated cccDNA, producing a 1-log (10-fold) reduction in cccDNA-derived transcripts. A further program update is targeted by year-end 2026.

What update did Precision BioSciences (DTIL) provide on its Duchenne muscular dystrophy trial?

Precision BioSciences announced activation of a second clinical site at Washington University School of Medicine for the FUNCTION-DMD trial of PBGENE-DMD. The company is targeting year-end 2026 for initial safety data from this Duchenne muscular dystrophy clinical trial.

Where can investors find Precision BioSciences’ updated corporate deck?

The updated Precision BioSciences corporate deck is available in the Investors section of its website at https://investor.precisionbiosciences.com. It summarizes clinical highlights, including PBGENE-HBV ELIMINATE-B data and progress on the FUNCTION-DMD trial for Duchenne muscular dystrophy.

Is the information about Precision BioSciences’ programs considered filed with the SEC?

No. The company states the information in the Regulation FD section is furnished, not filed, under the Securities Exchange Act. It is not subject to Section 18 liabilities and is only incorporated into other filings if specifically referenced.

What clinical timelines did Precision BioSciences specify for 2026?

Precision BioSciences is targeting year-end 2026 for two milestones: the next program update for PBGENE-HBV in chronic hepatitis B and initial safety data from the FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy.

Filing Exhibits & Attachments

3 documents

Other Documents